Search Results - "Cacho, Diego"

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer by Fernández Montes, Ana, Alonso Orduña, Vicente, Asensio Martínez, Elena, Rodríguez Salas, Nuria, Torres, Esperanza, Cacho Lavín, Diego, Rodríguez Alonso, Rosa María, Falcó, Esther, Oliva, Joan Carles, Cirera, Lluis, García Gómez, Jesus, Pericay, Carles

“…Abstract Background Patients with metastatic colorectal cancer (mCRC) and KRAS mutations have a poor prognosis, seemingly dependent on the location of the…”
Get full text

Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry by Cotes Sanchís, Almudena, Gallego, Javier, Hernandez, Raquel, Arrazubi, Virginia, Custodio, Ana, Cano, Juana María, Aguado, Gema, Macias, Ismael, Lopez, Carlos, López, Flora, Visa, Laura, Garrido, Marcelo, Martínez Lago, Nieves, Fernández Montes, Ana, Limón, María Luisa, Azkárate, Aitor, Pimentel, Paola, Reguera, Pablo, Ramchandani, Avinash, Cacho, Juan Diego, Martín Carnicero, Alfonso, Granja, Mónica, Martín Richard, Marta, Hernández Pérez, Carolina, Hurtado, Alicia, Serra, Olbia, Buxo, Elvira, Vidal Tocino, Rosario, Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Buyukhatipoglu, Hakan

“…Background Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and…”
Get full text

RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain by Badiola, Laura Basterretxea, Milagro, Nuria Lainez, Lavín, Diego Cacho, Peraita, Sandra López, Ibarbia, Mikel Arruti, Kareaga, Mireia Martínez, Fernández del Rivero, Teresa de Portugal, Otero, Diego Soto de Prado, López, Valentín Alija, Fernández, Carlos Álvarez, Emborujo, Alejandra Lacalle, Arnaiz, Irene Gil, Rodríguez, Ricardo Fernández, Verdún-Aguilar, Juan, Sagastibeltza, Naiara, Duran, Ignacio

“…The current available evidence on the management of metastatic renal cell cancer (mRCC) in real life is scarce in our environment. We present a summary of the…”
Get full text

Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study by Pericay, Carles, Fernández Montes, Ana, Alonso Orduña, Vicente, Macias Declara, Ismael, Asensio Martínez, Elena, Rodríguez Salas, Nuria, Torres, Esperanza, Cacho Lavín, Diego, Rodríguez Alonso, Rosa María, Falcó, Esther, Oliva, Joan Carles, Cirera, Lluis

“…The retrospective, observational RWD-ACROSS study analyzed disease characteristics, systemic treatment, and survival in patients with metastatic colorectal…”
Get full text

Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence by Jiménez-Fonseca, Paula, Gallardo, Enrique, Arranz Arija, Fernando, Blanco, Jesús Manuel, Callejo, Ana, Lavin, Diego Cacho, Costa Rivas, Marinha, Mosquera, Joaquín, Rodrigo, Alberto, Sánchez Morillas, Raúl, Vares Gonzaléz, María, Muñoz, Andrés, Carmona-Bayonas, Alberto

“…•Thromboprophylaxis should be considered in patients with ALK/ROS1+ stage IV lung cancer requiring systemic treatment.•Cautiously reintroduce an effective…”
Get full text

Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis by García Adrián, Silvia, González, Adán Rodríguez, de Castro, Eva Martínez, Olmos, Vanessa Pachón, Morán, Laura Ortega, del Prado, Purificación Martínez, Fernández, Mercedes Salgado, Burón, José David Cumplido, Escobar, Ignacio García, Galán, Joaquina Martínez, Pérez, Ana Isabel Ferrer, Neria, Fernando, Lavin, Diego Cacho, Hernández, Borja López de San Vicente, Jiménez-Fonseca, Paula, Muñoz Martín, Andrés J.

“…•Pancreatic carcinoma was associated with an incidence of thrombosis as high as 22%.•Venous thromboembolic events were associated with worse survival in this…”
Get full text

Immune checkpoint inhibitors-associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group by Sánchez Cánovas, Manuel, Moya Hernández, Miguel Ángel, Adoamnei, Evdochia, Cacho Lavin, Diego, Fernández Garay, David, Quintanar Verdúguez, Teresa, Rogado Revuelta, Jacobo, García Verdejo, Francisco José, García Adrián, Silvia, Ferrer Pérez, Ana Isabel, Guirao García, María Esperanza, López Robles, Javier, Mendiola, Jaime, Muñoz Martín, Andrés J

“…Both venous and arterial thrombotic events (VTE/AT) can be associated with Immune Checkpoint Inhibitors (ICI). However, there is a paucity of information…”
Get full text

Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group by Cánovas, Manuel Sánchez, Garay, David Fernández, Moran, Laura Ortega, Pérez, Jaime Rubio, Rubio, Carlos Miguel Guirao, de Mena, Miriam Lobo, Portero, Berta Obispo, Castro, Jesús Brenes, Lage, Yolanda, Lavin, Diego Cacho, Blanco, Ana Belen Rupérez, de Soignie, Ana Manuela Martín Fernández, Perejón, Jonatan Zacarías Benoit, Colomo, Laura Jiménez, Boluda, Noel Blaya, Moreno, Javier Bosque, Verduguez, Teresa Quintanar, Garrido, Carmen Rosa, Huertas, Roberto Martín, Puig, Carme Font i, Martín, Andrés Jesús Muñoz

“…Purpose Immune Checkpoint Inhibitors (ICI) can be associated with thrombotic events, both venous and arterial (VTE/AT). However, there is a paucity of…”
Get full text

Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group by Sánchez Cánovas, Manuel, Fernández Garay, David, Gómez Martínez, Francisco, Brozos Vázquez, Elena, Lobo de Mena, Miriam, García Adrián, Silvia, Pacheco-Barcía, Vilma, Cacho Lavin, Diego, Martínez de Castro, Eva, Martín Fernández de Soignie, Ana Manuela, Martínez, Elia, Rúperez Blanco, Ana Belén, García Escobar, Ignacio, Salvador Coloma, Carmen, Blaya Boluda, Noel, Guirao García, María Esperanza, Gambín Arroniz, Mariano, Muñoz Martín, Andrés J.

“…Purpose The CoVID-TE model was developed with the aim of predicting venous thrombotic events (VTE) in cancer patients with Sars-Cov-2 infection. Moreover, it…”
Get full text

The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Jimenez-Fonseca, Paula, Foy, Victoria, Raby, Sophie, Carmona-Bayonas, Alberto, Macía-Rivas, Lola, Arrazubi, Virginia, Cacho Lavin, Diego, Hernandez San Gil, Raquel, Custodio, Ana, Cano, Juana María, Fernández Montes, Ana, Mirallas, Oriol, Macias Declara, Ismael, Vidal Tocino, Rosario, Visa, Laura, Limón, María Luisa, Pimentel, Paola, Martínez Lago, Nieves, Sauri, Tamara, Martín Richard, Marta, Mangas, Monserrat, Gil Raga, Mireia, Calvo, Aitana, Reguera, Pablo, Granja, Mónica, Martín Carnicero, Alfonso, Hernández Pérez, Carolina, Cerdá, Paula, Gomez Gonzalez, Lucía, Garcia Navalon, Francisco, Pacheco Barcia, Vilma, Gutierrez Abad, David, Ruiz Martín, Maribel, Weaver, Jamie, Mansoor, Wasat, Gallego, Javier

“…Background: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced…”
Get full text

Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry by Pérez-Wert, Pablo, Custodio, Ana, Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Lecumberri, Arturo, Cacho Lavin, Diego, Losantos García, Itsaso, Fernández Montes, Ana, Cano, Juana María, Limón, María Luisa, Hernández San Gil, Raquel, Diez, Marc, Vidal Tocino, Rosario, Macías Declara, Ismael, Visa, Laura, Pimentel Cáceres, Paola, Gil Raga, Mireia, Martínez Moreno, Elia, Sauri, Tamara, Martín Richard, Marta, Granja, Mónica, Cerdà, Paula, Gómez González, Lucía, Mérida-García, Antonio, Ruiz Martín, Maribel, Gallego, Javier

“…Background Gastroesophageal adenocarcinoma in young adults (GCYA) counts for 10–15% of diagnoses. Previous studies have mainly focused on surgical outcomes in…”
Get full text

Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry by Alvarez-Manceñido, Felipe, Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Arrazubi, Virginia, Hernandez, Raquel, Cano, Juana M., Custodio, Ana, Pericay Pijaume, Carles, Aguado, Gema, Martínez Lago, Nieves, Sánchez Cánovas, Manuel, Cacho Lavin, Diego, Visa, Laura, Martinez-Torron, Alba, Arias-Martinez, Aranzazu, López, Flora, Limón, M. Luisa, Vidal Tocino, Rosario, Fernández Montes, Ana, Alsina, Maria, Pimentel, Paola, Reguera, Pablo, Martín Carnicero, Alfonso, Ramchandani, Avinash, Granja, Mónica, Azkarate, Aitor, Martín Richard, Marta, Serra, Olbia, Hernández Pérez, Carolina, Hurtado, Alicia, Gil-Negrete, Aitziber, Sauri, Tamara, Morales del Burgo, Patricia, Gallego, Javier

“…Background Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC)…”
Get full text

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry by Jimenez-Fonseca, Paula, Carmona-Bayonas, Alberto, Martinez-Torron, Alba, Alsina, Maria, Custodio, Ana, Serra, Olbia, Cacho Lavin, Diego, Limón, María Luisa, Sauri, Tamara, López, Flora, Visa, Laura, Granja, Mónica, Martínez Lago, Nieves, Arrazubi, Virginia, Vidal Tocino, Rosario, Hernandez, Raquel, Aguado, Gema, Cano, Juana María, Martín Carnicero, Alfonso, Mangas, Monserrat, Pimentel, Paola, Fernández Montes, Ana, Macias Declara, Ismael, Longo, Federico, Ramchandani, Avinash, Martín Richard, Marta, Hurtado, Alicia, Azkarate, Aitor, Hernández Pérez, Carolina, Serrano, Raquel, Gallego, Javier

“…Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for…”
Get full text

PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform by Lashey, Matthew David, Linares Espinos, Estefania, Basterretxea, Laura, Gurruchaga, Ibon, Gomez Mediavilla, Borja, Esteban, Brigida, Cacho, Diego, Congregado, Belen, Rivero Belenchon, Ines, Hernandez, Amaia, Sancho, Gemma, Lainez, Nuria, Buchser, David, Sanguedolce, Francesco, Duran, Ignacio

“…192 Background: It is well established that the monitoring and evaluation of PROs in cancer patients has a positive impact in both quality of life and overall…”
Get full text

PRO-WAVE1: Monitoring patient reported outcomes (PROs) in prostate cancer through Wave Health, a novel ePRO health platform by Cacho, Diego, Congregado, Belen, Rivero Belenchon, Ines, Linares Espinos, Estefania, Basterretxea, Laura, Sancho, Gemma, Lainez, Nuria, Buchser, David, Sanguedolce, Francesco, Gurruchaga, Ibon, Gomez Mediavilla, Borja, Esteban, Brigida, Hernandez, Amaia, Lashey, Matthew, Duran, Ignacio

“…114 Background: It is well established that the monitoring and evaluation of PROs in cancer patients has a positive impact in both quality of life and overall…”
Get full text

The potential of transcriptomic profiling to predict immune-checkpoint inhibitor (ICIs) response in locally advanced (La) and metastatic urothelial carcinoma (mUC) by Caramelo, Belen, Muñoz Unceta, Nerea, Freire, Javier, Varela, Ignacio, Martin, David, Del Carmen, Sofía, Azueta, Ainara, Diaz, Pilar, Garcia-Berbel, Pilar, Sagastibelza Marinelarena, Naiara, Rey-Cárdenas, Macarena, Castellano, Daniel, Climent, Miguel Ángel, Puente, Javier, Irure, Juan, Revuelta, Laura, Genre, Fernanda, Cacho, Diego, Gómez, Javier, Duran, Ignacio

“…668 Background: Immune checkpoint inhibitors (ICIs) have proven to be an effective therapy for locally advanced (La) and metastatic (mUC) urothelial carcinoma…”
Get full text

Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution by Sotelo, Marta, Muñoz-Unceta, Nerea, Matorras, Antonio, Jara, Pablo, Castro, Clara, Cacho, Diego, Caramelo, Belén, Azueta, Ainara, Durán, Ignacio

“…Purpose Immune checkpoint inhibitors (ICIs) have been incorporated in the treatment of metastatic urothelial carcinoma (mUC) upon platinum-based chemotherapy…”
Get full text

Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases by Donas, Jesus Garcia, de Velasco, Guillermo, Alonso Gordoa, Teresa, Chamorro, Jesús, Rosero, Diana, Etxaniz, Olatz, Perez-Gracia, Jose Luis, Pinto, Alvaro, Duran, Ignacio, Cacho, Diego, Barba, María, Yagüe, Monica, Borrega, Pablo, Lázaro, Martín, Rodriguez, Laura, Villalobos Leon, Maria Laura L., Garcia Sanchez, Lourdes, Cuellar, M. Andres, Rodriguez-Moreno, Juan Francisco

“…Abstract only 4577 Background: Cancer is recognized as a major risk factor for severe COVID19. However little is known about the impact of oncologic treatments…”
Get full text

Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience by Serrano, Marina, Muñoz-Unceta, Nerea, Alonso, Lucía Andrea, Azueta, Ainara, Gutiérrez Baños, José Luis, Ferreira, Laura, Domínguez, Mario, Torres Zurita, Albero, Ballestero, Roberto, Cacho, Diego, López-Brea, Marta, Sotelo, Marta, Campos-Juanatey, Félix, Ramos Barseló, Enrique, Duran, Ignacio

“…Purpose Neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) patients has proven beneficial in overall survival. However, the optimal regimen is…”
Get full text

Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study by García-Donas, Jesús, de Velasco, Guillermo, Madurga, Rodrigo, Chamorro, Jesús, Rosero, Diana, Etxaniz, Olatz, Pérez-Gracia, Jose Luis, Pinto, Álvaro, Cacho, Diego, Barba, María, Borrega, Pablo, Lázaro, Martín, Rodriguez, Laura, Villalobos, Laura, García, Lourdes, Cuellar, Andrés, Solís-Hernández, María Pilar, González, Amalia, Pernaut, Cristina, Rodríguez-Moreno, Juan Francisco

“…Background Cancer is a risk factor for developing severe COVID19. Additionally, SARS-CoV2 has a special tropism for renal cells and complications like…”
Get full text